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Introduction
Treatment of sputum retention and the associated chronic 
infection in the airways of people with cystic ﬁbrosis 
involves several therapeutic approaches. Antibiotics are 
administered to suppress infection (Southern et al 2004, 
Ryan et al 2003, Smyth and Walters 2003), manual 
physiotherapy techniques and other physical interventions 
are used to clear infected mucus from the airways (van der 
Schans et al 2000), and various mucoactive medications are 
used to improve the properties of the mucus to facilitate 
its clearance (Jones and Wallis 2010, Wark and McDonald 
2009). One of these mucoactive medications is recombinant 
human deoxyribonuclease, or dornase alpha (Pulmozyme®). 
It reduces the viscosity of sputum in people with cystic 
ﬁbrosis by cleaving strands of the deoxyribonucleic acid 
(DNA) released by neutrophils (Lieberman 1968). This 
makes the sputum ﬂow more easily (Shak et al 1990). 
Regular use of dornase alpha improves lung function and 
quality of life, and reduces the number and severity of 
respiratory exacerbations (Hubbard et al 1992, Ramsey et 
al 1993, Fuchs et al 1994).
Although dornase alpha has been used widely in the 
management of cystic ﬁbrosis for more than 15 years, the 
optimal timing of administration with respect to physical 
airway clearance techniques is still unclear. During its 
clinical development, trials allowed dornase alpha to be 
administered either before or after physical airway clearance 
techniques. Only recently have trials started to address this 
potentially important aspect of its administration.
Fitzgerald and colleagues (2005) compared administration 
of dornase alpha 30 min before and 30 min after physical 
airway clearance techniques in children and adolescents 
with cystic ﬁbrosis. They found that the two timing 
regimens had similar effects on measures of lung function, 
quality of life, and peak exercise capacity. In a similar study, 
van der Giessen and colleagues (2007) also found that the 
regimens had non-signiﬁcant differences in most measures 
of lung function. However, as their primary outcome, they 
included an additional measure: maximal expiratory ﬂow at 
25% of the forced vital capacity (FVC). This outcome was 
signiﬁcantly better when dornase alpha was administered 
before physical airway clearance techniques. Wilson and 
colleagues (2007) performed a similar study in adults 
and children with cystic ﬁbrosis and found no signiﬁcant 
differences for most outcomes. However, in those outcomes 
that did differ (ie, forced expiratory ﬂow rate between 25% 
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What is already known on this topic: The timing of 
dornase alpha in relation to physiotherapy techniques 
may alter the effect of these two interventions on airway 
clearance. However, this has not been examined in 
adults with cystic ﬁbrosis.
What this study adds: The timing of dornase alpha 
does not strongly inﬂuence the efﬁcacy of the airway 
clearance regimen in adults with cystic ﬁbrosis. 
Therefore dornase alpha can be timed according to 
convenience, patient preference or to accommodate 
other medications in the treatment regimen.
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and 75% of the FVC and one measure of quality of life), 
administration of dornase alpha before physical airway 
clearance techniques was less favourable. These somewhat 
conﬂicting results make it difﬁcult for clinicians to advise 
people – especially adults – with cystic ﬁbrosis about how 
to structure their treatment regimen for airway clearance.
This study was designed to compare the effectiveness of 
dornase alpha administered before versus after airway 
clearance techniques, in adults with cystic ﬁbrosis. We 
were also interested in whether the response of some 
subgroups of participants might differ from others, deﬁned 
by their baseline lung function, or by their baseline sputum 
production. Therefore, the research questions for this study 
were:
1. Does the inhalation of dornase alpha before or after 
airway clearance techniques inﬂuence the effect on 
lung function?
2. Does the inhalation of dornase alpha before or after 
airway clearance techniques inﬂuence 24-hour 
sputum production, the percentage of daily sputum 
produced during the airway clearance regimen, 
oxygen saturation, peak oxygen consumption during 
an incremental exercise test, oxygen desaturation 
during exercise, and quality of life?
3. Do particular subgroups of participants differ in their 
response to the two regimens?
Method
Design
A randomised trial with concealed allocation and intention-
to-treat analysis and blinding of participants, therapists, 
and assessors was undertaken at the Cystic Fibrosis Unit 
at Westmead Hospital, Sydney. Participants were recruited 
from the outpatient clinic of the Cystic Fibrosis Unit. 
Before entry into the study, each participant had their 
airway clearance techniques reviewed and optimised by 
one investigator (JRB). The range of techniques used 
included conventional postural drainage and percussion, 
positive expiratory pressure via a mask interface, and active 
cycle of breathing techniques (Pryor and Prasad 2008). 
All participants were then encouraged to perform at least 
15 min of the techniques each day for the 28 days before 
randomisation was scheduled, to ensure familiarity with 
the techniques. Participants were assessed in the Cystic 
Fibrosis Unit 14 days prior to randomisation and on the day 
of randomisation (Day 0) to conﬁrm clinical stability at 
the time of enrolment. Randomisation occurred within the 
hospital pharmacy to maintain concealment of the random 
allocation list, which used a block size of four participants. 
Dornase alpha and placebo in blinded packaging were 
dispensed through the hospital pharmacy to maintain 
blinding. Participants inhaled dornase alpha before and 
placebo after performing their airway clearance techniques 
for 14 days, and placebo before and dornase alpha after the 
techniques for the other 14 days. The order of the two 14-
day periods was randomised. Participants were assessed at 
the beginning and end of each 14-day period, as presented 
in Figure 1.
Participants
Outpatients attending the Cystic Fibrosis Unit were eligible 
to participate if they were aged 18 years or more and had a 
diagnosis of cystic ﬁbrosis conﬁrmed by a clinical history, 
a positive sweat test and/or nasal potential difference 
measurement. Exclusion criteria were: FVC less than 40% 
of the predicted value, clinical instability (> 10% change in 
forced expiratory volume in 1 sec (FEV1) over 14 days) or 
hospitalisation within the 14 days prior to randomisation, 
current use of dornase alpha, inability to perform 
reproducible lung function tests, and poor adherence with 
therapy (deﬁned as < 85% adherence based on self report 
and vial counts).
Intervention
The experimental intervention was to take dornase alpha 
after and the placebo before performing the airway clearance 
techniques once daily for 14 days. The control intervention 
was to take dornase alpha before and the placebo after the 
airway clearance techniques for 14 days.
The active ampoules contained 2.5 mg of dornase alpha in 
2.5 mL. The placebo ampoules contained 2.0 mL of 0.9% 
saline. To preserve blinding, all ampoules were stored 
under refrigeration – a requirement of dornase alpha. Each 
participant was supplied with two jet nebulisersa to be 
used for inhaling the trial solutions. The nebulisers were 
colour-coded to match the trial solution packaging, but were 
otherwise identical. Separate nebulisers were necessary 
because dornase alpha can be denatured by traces of other 
compounds in the nebuliser chamber. At the start of the 
trial, all nebuliser pumps were tested to ensure that they 
produced adequate ﬂow rates (6–8 L/min) with sufﬁcient 
driving pressures (10–12 pounds per square inch, 69–83 
kPa).
All participants received usual medical and allied health 
management by the Cystic Fibrosis Unit if required during 
the trial period, and were encouraged to continue with their 
other usual therapies. Participants who were already taking 
bronchodilators were advised to inhale them before the 
inhalation of the ﬁrst trial solution at each daily treatment 
session. Participants who were already taking inhaled 
antibiotics were advised to inhale them after the inhalation 
of the second trial solution at each daily treatment session.
Demographic and clinical data including age, gender, 
body mass index, bacterial colonisation of sputum, usual 
medication use, lung function, oxyhaemoglobin saturation, 
and quality of life were recorded at baseline (Day 0).
On Day 1, participants received the blinded therapy under 
clinical supervision. Lung function was measured before 
and after each nebulisation and both before and after the 
physical airway clearance techniques to assess any acute 
changes during the intervention. Cumulative sputum 
weight was measured after each spirometry measurement. 
Subsequent doses were inhaled independently at home. On 
the ﬁrst day of the second treatment arm (Day 15) the same 
measurements were performed.
Outcome measures
All outcome measures were recorded at the start and 
end of the ﬁrst 14-day period (Days 1 and 14) and at the 
start and end of the second 14-day period (Days 15 and 
28), as presented in Figure 1. All measurements were 
performed by an investigator who was blinded to whether 
the participant was in the experimental or control arm of 
the study. Participants were also blinded throughout the 
study, including when they completed the quality of life 
questionnaires.
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Review of physical airway clearance techniques and assessment of clinical status
(n = 20)
Withdrew (n = 3)
 Time constraints (n = 3)
Randomised (n = 17)
(n = 9)                                                                                    (n = 8)
Day –14
Experimental arm
 usual care
 dornase alpha after 
airway clearance 
techniques
Control arm
 usual care
 dornase alpha before 
airway clearance 
techniques
Measured lung function, sputum weight, oxygenation, exercise capacity and quality of life 
(n = 9)                                                                                    (n = 8)
Lost to follow-up (n = 0)
Lost to follow-up (n = 0)
Lost to follow-up (n = 0)
Lost to follow-up (n = 0)
Day 1
Day 0
Measured lung function, sputum weight, oxygenation, exercise capacity, and quality of life
(n = 9)                                                                                    (n = 8)
Measured lung function, sputum weight, oxygenation, exercise capacity, and quality of life
(n = 9)                                                                                    (n = 8)
Day 14
Day 15
Measured lung function, sputum weight, oxygenation, exercise capacity, and quality of life
(n = 9)                                                                                    (n = 8)
Day 28
Control arm
 usual care
 dornase alpha 
before airway 
clearance 
techniques
Experimental arm
 usual care
 dornase alpha 
after airway 
clearance 
techniques
Patients screened for participation (n = 30)
Excluded (n = 10)
 Already taking dornase alpha (n = 7)
 Declined to participate (n = 3)
'JHVSF Design and ﬂow of participants through the trial.
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Lung function was measured using a standard spirometerb 
according to American Thoracic Society guidelines 
(American Thoracic Society 1995). The spirometric 
measures recorded were FEV1 in litres and as a percentage 
of the predicted value, and FVC as a percentage of the 
predicted value. Predicted values were calculated using the 
equations of Knudson and colleagues (1976).
The sputum expectorated within a 24-hr period was 
collected in a plastic ﬂask by the participants and weighed 
on an electronic scale. The amount of sputum expectorated 
during a session of airway clearance techniques was 
collected independently in a separate ﬂask, so that it could 
be calculated as a proportion of the 24-hour sputum weight.
Oxygenation was measured using a standard pulse oximeter 
with a ﬁnger probe. Stable readings were required for 10 
sec before recording the data. Oxygenation was also 
continuously monitored during the exercise test (described 
below) to determine the greatest reduction during the 
exercise test.
Exercise capacity was measured using the original 10-m 
shuttle test (Singh et al 1994) or the Multi Stage Fitness Test 
(Léger and Lambert 1989). Oxygen uptake at peak exercise 
was estimated from the exercise testing using standard 
equations (Singh et al 1994, Léger and Lambert 1989).
Participants completed the adult Australian Cystic Fibrosis 
Quality of Life (CFQOL) questionnairec independently. 
This questionnaire results in an overall score between 0 
(worst) and 100 (best).
Data analysis
A change in FEV1 of 10% is used as a threshold for Australian 
government reimbursement of the cost of dornase alpha. We 
therefore nominated 10% as the between-group difference 
we sought to identify. Assuming a within-patient SD of 10%, 
18 participants would provide 80% power, at the 2-sided 
5% signiﬁcance level, to detect a 10% difference in FEV1 
between the experimental and control arms as statistically 
signiﬁcant. We recruited 20 participants to allow for loss to 
follow-up.
Continuous data were summarised as means and standard 
deviations and categorical data were summarised as 
frequencies and percentages. The normality of the 
distribution of the data was examined with the Kolmogorov-
Smirnov test. Although some of the raw data were not 
normally distributed, the within-subject differences were 
normally distributed. Therefore the data were analysed 
using parametric statistics. Between-group differences in 
change from baseline were analysed using paired t-tests. 
Mean differences (95% CI) between groups are presented. 
Data were analysed by intention-to-treat. The effect 
of the timing regimen on FEV1 was correlated against 
baseline FEV1 and against baseline sputum production, 
and the strength of the relationship was reported using the 
coefﬁcient of determination (r2).
Results
Flow of participants, therapists and centres 
through the trial
Thirty adults from the Cystic Fibrosis Unit were screened 
for eligibility. Twenty met the initial eligibility criteria, but 
three withdrew during the 14-day period of regular use 
of airway clearance techniques, citing time constraints. 
The remaining 17 participants were randomised: 9 to the 
experimental arm (dornase alfa after airway clearance 
techniques) ﬁrst (post-pre group), and 8 to the control arm 
(dornase alfa before airway clearance techniques) ﬁrst (pre-
post group). The ﬂow of participants through the trial is 
illustrated in Figure 1. The characteristics of the participants 
were similar at the start of each arm of the study (Table 1 
and the ﬁrst two columns of Table 2). Twelve participants 
were using positive expiratory pressure as their physical 
airway clearance technique. Seven participants were using 
active cycle of breathing techniques, of whom 4 were using 
percussion as well. One participant used positive expiratory 
pressure once daily and percussion once daily.
5BCMFCharacteristics of participants.
Characteristic All 
(n = 17)
Exp ﬁrst 
(n = 9)
Con ﬁrst 
(n = 8)
Age (yr), mean (SD) 25 (11) 27 (15) 23 (4)
Gender, n males (%) 9 (53) 5 (56) 4 (50)
BMI (kg/m2), mean (SD) 20.6 (3.3) 20.9 (4.1) 20.3 (2.2)
Bacterial colonisation of sputum, n (%)
 Pseudomonas aeruginosa 16 (94) 8 (89) 8 (100)
 Staphylococcus aureus 5 (29) 1 (11) 4 (50)
 MRSA 1 (6) 0 (0) 1 (13)
 Burkholderia cepacia 1 (6) 1 (11) 0 (0)
Regular therapies, n (%)
 exercise 8 (47) 5 (56) 4 (50)
 bronchodilator 10 (59) 5 (56) 5 (63)
 antiinﬂammatory 7 (41) 3 (33) 4 (50)
 oral steroids 0 (0) 0 (0) 0 (0)
 antibiotics 10 (59) 4 (44) 5 (63)
Dornase alpha naïve, n (%) 11 (65) 7 (78) 4 (50)
Exp = experimental condition (dornase alpha after physical airway clearance techniques), Con = control 
condition (dornase alpha before physical airway clearance techniques), BMI = body mass index, MRSA 
= Methicillin-resistant Staphylococcus aureus.
Journal of Physiotherapy 2011  Vol. 57  –  © Australian Physiotherapy Association 2011 227
The airway clearance regimen, including tailoring of 
the physical techniques and conﬁrming the appropriate 
nebulisation procedures, was determined by the Cystic 
Fibrosis Unit physiotherapist, who had 6 years of clinical 
experience, including 4 years in the cystic ﬁbrosis area. 
The Cystic Fibrosis Unit of Westmead Hospital in Sydney 
was the only centre to recruit and test patients in the trial. 
The Cystic Fibrosis Unit managed approximately 60 adult 
patients during the time of the study.
Compliance with trial method
All randomised participants completed both arms of the trial. 
According to diary card entries and vial counts, compliance 
with the allocated therapies was > 85%. No participants 
in either arm had adverse clinical changes during the 
intervention that required cessation of the intervention. 
One participant with a history of recurrent haemoptysis had 
a single episode after the ﬁrst 14-day intervention period 
(during which he was taking dornase alpha before airway 
clearance techniques). This was considered unlikely to be 
related to treatment and resolved spontaneously despite 
continuation of the allocated treatment regimen.
Effect of intervention
Group data for all outcomes for the experimental and 
control interventions are presented in Tables 2 and 3, while 
individual data are presented in Table 4 (see eAddenda for 
Table 4).
The timing of the inhalation of dornase alpha did not have 
statistically signiﬁcant effects on lung function. The best 
estimate of the average effect of changing from inhaling 
dornase alpha before to after the physical techniques was 
to increase FEV1 by only 40 mL (95% CI –140 to 230 
mL). When the FEV1 data were considered in terms of a 
percentage of the predicted value, the best estimate of the 
effect and the limits of the conﬁdence interval all indicated 
that any effect was too small to be clinically worthwhile. 
5BCMF Mean (SD) for outcomes for each group, mean (SD) difference within groups, and mean (95% CI) differences 
between groups.
Groups Difference within 
groups
Difference between 
groups
Start End End minus Start End minus Start
Exp 
(n = 17)
Con 
(n = 17)
Exp 
(n = 17)
Con 
(n = 17)
Exp Con Exp minus Con
FEV1 (L)
2.29 
(0.81)
2.35 
(0.95)
2.31 
(0.83)
2.32 
(0.85)
0.01 
(0.21)
–0.03 
(0.28)
0.04 
(–0.14 to 0.23)
FEV1 (% predicted)
67 
(22)
68 
(25)
68 
(23)
68 
(24)
1 
(6)
0 
(7)
1 
(–4 to 6)
FVC 
(% predicted)
83 
(22)
81 
(23)
81 
(23)
84 
(20)
–2 
(6)
3 
(7)
–6 
(–11 to 0)
SpO2 (%)
97 
(2)
96 
(5)
97 
(2)
96 
(4)
0 
(1)
0 
(2)
0 
(–1 to 1)
Estimated VO2 
peak 
(mL/kg/min)
27 
(8)
27 
(8)
26 
(7)
28 
(10)
0 
(2)
1 
(3)
–1 
(–3 to 2)
SpO2 change 
with exercise 
(absolute %)
–4.8 
(4.0)
–4.7 
(3.3)
–5.2 
(4.1)
–4.6 
(3.7) 
(n = 16)
–0.4 
(1.2)
0.2 
(1.6)
–0.8 
(–1.8 to 0.3)
Quality of life 
(0 to 100)
73 
(9)
71 
(13)
73 
(12)
74 
(10)
0 
(10)
3 
(10)
–3 
(–9 to 3)
Shaded row = primary outcome, Exp = experimental condition (dornase alpha after physical airway clearance techniques), Con = control 
condition (dornase alpha before physical airway clearance techniques), FEV1 = forced expiratory volume in 1 sec, SpO2% = percentage 
saturation of oxyhaemoglobin estimated by pulse oximetry, VO2 peak = oxygenation consumption at peak exercise
5BCMF Mean (SD) for outcomes for each group at the end of the intervention period, and mean  
(95% CI) difference between groups.
Groups Difference between groups
Exp 
(n = 17)
Con 
(n = 17)
Exp minus Con
24-hour sputum weight (g) 21 
(23)
24 
(36)
–3 
(–12 to 7)
Proportion of 24-hr sputum obtained during airway 
clearance regimen (%)
17 
(15)
23 
(25)
–5 
(–15 to 4)
Exp = experimental condition (dornase alpha after physical airway clearance techniques), Con = control condition (dornase alpha before 
physical airway clearance techniques)
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FVC tended to favour the inhalation of dornase alpha before 
airway clearance techniques, but the result was only of 
borderline statistical signiﬁcance.
Daily sputum production did not appear to be inﬂuenced 
by the timing regimen, and nor did the amount of sputum 
obtained during the airway clearance regimen as a 
proportion of the daily amount.
There was little change in resting oxygen saturation levels 
in all participants throughout both arms of the study. 
The timing of inhalation of dornase alpha did not have a 
signiﬁcant effect on this outcome. Exercise capacity was 
also quite stable among all participants, with no signiﬁcant 
effect due to the timing of dornase alpha. On average, 
participants showed a fall in oxygenation of about 5% 
(absolute) during the exercise test at the start and end of 
both arms of the study.
The quality of life data showed that most patients’ quality 
of life scores improved during the study regardless of the 
timing of dornase alpha. Change in quality of life score 
showed a good correlation with change in FEV1 (r2 = 0.4, 
p < 0.001). The effect of the timing regimen on FEV1 was 
not signiﬁcantly correlated with baseline FEV1 (r2 = 0.11). It 
was also not signiﬁcantly correlated with baseline sputum 
production (r2 = 0.02).
Discussion
This is the ﬁrst study to consider the effect of the timing 
of dornase alpha in relation to airway clearance techniques 
in adults with cystic ﬁbrosis. The main ﬁnding is that the 
timing of dornase alpha does not have a substantial impact 
on clinical outcomes over a 14-day period. This ﬁnding is 
likely to be accurate because many aspects of the study 
design eliminated sources of potential bias. For example, 
the groups were similar on their baseline measures and are 
likely to have been similar on unmeasured characteristics 
as well, due to the use of randomisation and concealment of 
allocation, which circumvents some potential confounders 
of the randomisation process. Potential sources of bias were 
also eliminated from the outcome data through blinding 
of participants, the assessors, and the physiotherapist who 
explained the intervention to the participants and who 
taught them how to administer the trial solutions. The 
study was adequately powered, with no loss to follow-
up after randomisation, resulting in a conﬁdence interval 
around the primary outcome that excluded the possibility 
that the timing of dornase alpha has clinically important 
effects. Previous large multi-centre studies have shown that 
the maximum effect of dornase alpha on FEV1 is achieved 
within the ﬁrst 7 to 14 days (Fuchs et al 1994), so presumably 
the duration of the study arms was sufﬁcient to identify the 
effect on lung function.
In addition to the strengths of the study design, we 
acknowledge that there were some limitations in the 
methods. Peak oxygen consumption was not measured 
directly and one of two exercise tests was used to estimate 
it. Also, there was a minimal washout period between the 
two study arms. However, there was minimal difference 
between the groups at the end of the ﬁrst treatment period, 
suggesting that the lack of a long washout period was not a 
substantial confounder.
The results of the study were also consistent with similar 
studies in children with cystic ﬁbrosis. Fitzgerald and 
colleagues (2005) examined the effect of timing of dornase 
alpha in children with less severe cystic ﬁbrosis lung disease 
than our cohort. This trial also did not identify an effect of 
timing on any outcome. Interestingly, post-hoc analysis of 
their cohort identiﬁed that inhalation of dornase alpha after 
physical airway clearance techniques was more beneﬁcial 
for FEV1 in those participants who were colonised with 
Pseudomonas aeruginosa. Although virtually all the 
participants in our study were colonised with Pseudomonas 
aeruginosa, it did not demonstrate a clear advantage of 
inhaling dornase alpha after physical airway clearance 
techniques. In a different study, dornase alpha inhaled 30 
min before physical airway clearance techniques improved 
expiratory ﬂow at 25% of the forced vital capacity (van 
der Giessen et al 2007). However, FEV1, FVC, and visual 
analogue scores of sputum and cough were not affected 
differently by the two timing regimens in that study.
Although the other studies in this area reported the amount 
of sputum expectorated, ours was the only study to report 
the amount of sputum obtained during the airway clearance 
regimen as a proportion of daily sputum production. We 
believe this is an important measure because it reﬂects 
the immediate efﬁcacy of airway clearance interventions 
and the extent to which the person with cystic ﬁbrosis will 
be productive of sputum throughout the remainder of the 
day when they may be undertaking work, study or social 
activities. On average, about one-ﬁfth of daily sputum 
production occurred during the airway clearance regimen.
The correlational analyses we conducted conﬁrmed that our 
overall result – the timing of dornase alpha inhalation had 
little effect on lung function – can be considered applicable 
to all people with cystic ﬁbrosis who meet the eligibility 
criteria for this study. That is, the lack of an effect on lung 
function in this study was not due to a real effect in some 
participants being diluted or masked by a weak or adverse 
effect in participants with different characteristics such as 
baseline lung function or baseline sputum production.
The knowledge that the timing of dornase alpha in relation 
to physical airway clearance techniques does not affect 
clinical outcomes is useful for patients and clinicians, 
because the regimen of dornase alpha can be prescribed 
according to other priorities. For most patients, the timing of 
dornase alpha in relation to airway clearance can be tailored 
to patient preferences or timing in relation to other inhaled 
therapies. The correlation between change of quality of life 
scores and change in FEV1 suggests that the majority of 
patients can assess a true improvement subjectively. N-of-
1 trials may therefore be useful in determining a suitable 
timing regimen for an individual patient.
In summary, the timing of dornase alpha inhalation does 
not appear to have a strong inﬂuence on the efﬁcacy 
of the overall airway clearance regimen in adults with 
cystic ﬁbrosis. The inhalation of dornase alpha can be 
prescribed according to convenience, patient preference, 
or to accommodate the timing of other medications in the 
treatment regimen. Q
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